Susquehanna International Group, LLP Crinetics Pharmaceuticals, Inc. Transaction History
Susquehanna International Group, LLP
- $641 Billion
- Q4 2024
A detailed history of Susquehanna International Group, LLP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 50,251 shares of CRNX stock, worth $1.69 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,251
Previous 49,815
0.88%
Holding current value
$1.69 Million
Previous $2.54 Million
0.98%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CRNX
# of Institutions
256Shares Held
82.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$305 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$209 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$206 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$182 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$144 Million10.24% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.8B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...